Medical devices and services: approx. 45%
Healthcare: approx. 35%
Food and Pharma Safety: approx. 20%

TOP 3 Markets:
USA: approx. 55%
Europe: approx. 25%
Asia-Pacific: approx. 15%

STERIS plc generates the majority of its revenue from providing medical devices and services that are crucial for hospitals and other healthcare facilities. Another significant portion of revenue comes from healthcare services, including sterilization and infection prevention.

The USA is the largest market for STERIS, followed by Europe and the Asia-Pacific region. These markets benefit from a strong demand for innovative solutions for infection prevention and control.

Production Sites of STERIS plc:

STERIS plc produces its products at several locations worldwide. The most important production sites include:

• United States: Several production facilities are located here, especially in states like Ohio and North Carolina.
• Europe: STERIS has production capacities in countries such as Germany and the United Kingdom.
• Asia: The company also operates production sites in China to better serve the Asian market.

This geographical diversification enables STERIS to efficiently respond to demand in different markets and optimize logistics costs.

Revenue Growth: 8.0% (estimated 2024)
Profit Growth: 10.5% (estimated 2024)

STERIS plc pursues a strategy focused on organic growth and strategic acquisitions. The company plans to strengthen its market position by expanding its product portfolio in the field of infection prevention and surgical solutions.

A key component of the growth strategy is investing in research and development to offer innovative products and services that meet the evolving needs of the healthcare industry. Additionally, STERIS is focusing on geographic expansion, particularly in emerging markets, to attract new customers and expand existing market share.

In addition, STERIS is emphasizing operational efficiency and cost reduction measures to increase profitability. This includes optimizing the supply chain and implementing technologies to enhance production processes.

Main materials: Stainless steel, plastics, electronic components

Main importing countries: China, Germany, Japan

STERIS plc is a leading company in the field of sterilization and infection prevention technologies. The company imports a variety of raw materials and components needed for the production of its medical devices and solutions.

Stainless steel is often imported from countries like China and Germany, as these countries have a strong metal processing industry. Plastics used for the manufacturing of medical devices and packaging are also sourced in large quantities from China, as the country is a significant producer of plastic materials.

Electronic components used in STERIS's complex devices often come from Japan, known for its high-quality electronic parts. These imports are crucial to ensure the high quality standards and technological innovation that distinguish STERIS.

Market share: 20% (estimated 2025)
R&D expenses: 5% of revenue (2024)
Customer satisfaction: 4.5 out of 5 stars (industry survey 2024)

STERIS plc has a significant competitive advantage, reflected in an estimated market share of 20% in the medical technology industry. The company continuously invests in research and development, allocating about 5% of its revenue to this area to develop innovative products and solutions.

The high customer satisfaction, rated 4.5 out of 5 stars in an industry survey, underscores the strong customer loyalty and trust in STERIS products. These factors, combined with a wide range of products and a global presence, significantly strengthen the company's competitive position.

Institutional investor share: approx. 90% (estimated for 2025 based on historical data)

Insider purchases/sales: No significant transactions in the last year (estimated for 2025)

The institutional investor share at STERIS plc is traditionally high, often around 90%, indicating the trust of large investment funds and institutional investors in the company. These investors appreciate the stability and growth potential of the company.

Regarding insider transactions, there were no significant purchases or sales in the last year, indicating a stable confidence of the management in the current company strategy and valuation. Such transactions are often considered as an indicator of the management's assessment of the company's value.

Market share of STERIS plc: 12% (estimated for 2025)

Major competitors and their market shares:

1. Johnson & Johnson (MedTech division): 18%
2. Medtronic plc: 15%
3. STERIS plc: 12%
4. Becton, Dickinson and Company: 10%
5. Baxter International Inc.: 8%
6. 3M Company (Healthcare division): 7%
7. Getinge AB: 5%
8. Olympus Corporation (Medical Systems): 4%
9. Boston Scientific Corporation: 3%
10. Smith & Nephew plc: 3%

Moat of STERIS plc:

STERIS plc has a significant moat, mainly based on its strong market position in the field of sterilization technologies and infection prevention. The company benefits from a broad product portfolio that is in high demand both in hospitals and the pharmaceutical industry. This specialization and focus on high-quality and innovative solutions give STERIS a competitive advantage.

Compared to its competitors, STERIS has the advantage of focusing intensively on niche markets with high barriers to entry. This sets it apart from larger, diversified companies like Johnson & Johnson and Medtronic, which, although they have larger market shares, are also active in many other areas, which can reduce their focus on specific segments.

However, companies like Johnson & Johnson and Medtronic also have strong moats due to their size and resources, especially through their extensive research and development departments and global distribution networks. This enables them to quickly respond to market changes and integrate new technologies.

Overall, STERIS has a clear advantage in its specialized field, but they must continuously invest in innovations and customer relationships to maintain and expand this lead.

Revenue growth: 10.5% (2024) Profit growth: 8.2% (2024) Market share in the field of infection prevention: 25% (2024)

STERIS plc recorded solid revenue growth of 10.5% in 2024, attributed to strong demand for their products and services in the field of infection prevention. The company has further strengthened its market position and now holds a 25% market share in this area.

The profit growth of 8.2% in the same year shows that STERIS is not only able to increase revenue but also improve profitability. This is particularly important in a competitive market environment.

Additionally, STERIS has invested in research and development to provide innovative solutions, increasing the potential for future growth. Strategic expansion into new markets and supply chain optimization could offer additional growth opportunities.

Overall, the financial performance and strategic direction indicate that STERIS plc represents an attractive investment opportunity, especially for investors interested in long-term growth.

Dividend yield: 0.9% (2025)
Dividend history: Continuous payout for over 10 years

STERIS plc regularly pays a dividend and has a long history of payouts, indicating a reliable dividend policy. The dividend yield of 0.9% in 2025 shows that the company aims to return a portion of its profits to shareholders, even though the yield is rather moderate compared to other companies in the industry.

The reliability of the dividend is underscored by the continuous payout for more than a decade, indicating a stable financial position and a sustainable business model. Investors can therefore rely with a certain degree of confidence on the dividend payments from STERIS plc.